Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257063 | 0.82 | AKR1B1 (0.35) | RIPK1MAP2K2MAP2K1TNIK | |
| SCHEMBL2791884 | 0.79 | PNMT (0.31) | MAP2K2MAP2K1 | |
| SCHEMBL8104506 | 0.78 | IDO1 (0.36) | ERN1 | |
| SCHEMBL1477460 | 0.77 | SLC6A4 (0.40) | MAP2K2MAP2K1 | |
| SCHEMBL18653548 | 0.77 | LOXL2 (0.38) | MAP2K2MAP2K1 | |
| SCHEMBL20560697 | 0.77 | IDO1 (0.33) | MAP2K1 | |
| SCHEMBL26586520 | 0.77 | — | — | |
| SCHEMBL1131149 | 0.77 | — | — | |
| SCHEMBL30219553 | 0.77 | ERN1 (0.34) | ERN1MAP2K2MAP2K1 | |
| SCHEMBL1440125 | 0.77 | ERN1 (0.34) | ERN1MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | SLC9A1 727/4885RIPK1 834/4885ERN1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.